Previous 10 | Next 10 |
Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today releases...
Nemaura Medical press release ( NASDAQ: NMRD ): Q1 GAAP EPS of -$0.17. Cash and cash equivalents at June 30, 2022 were approximately $14.8M, as compared to $17.7M at March 31, 2022. For further details see: Nemaura Medical GAAP EPS of -$0.17
Loughborough, England, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting perso...
Nemaura Medical (NASDAQ: NMRD) was featured in the Bell2Bell Podcast , a part of IBN’s (InvestorBrandNetwork) sustained effort to provide specialized content distribution via widespread syndication channels. Dr. Faz Chowdhury, chairman and CEO of Nemaura, joined the latest episo...
LOS ANGELES, Aug. 08, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell...
FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Nemaura Medical Granted UK Trademark “Meta Score,” a Digital Biomarker Term for its Metabolic Health Program.” Nemaura Medical, Inc. (NASDAQ: N...
Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today announce...
FinancialBuzz.com’s latest Behind the Buzz Show: Featuring Our Corporate Overview on Nemaura Medical, Inc. Nemaura Medical, Inc. (NASDAQ: NMRD) evolved from a microsystem-based drug delivery platform that was developed in 2011. Since then, we have expanded t...
Loughborough, England, July 21, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting perso...
Gainers: Rubicon Technology ( RBCN ) +68% . Faraday Future Intelligent Electric ( FFIE ) +65% . Ra Medical Systems ( RMED ) +61% . Xilio Therapeutics ( XLO ) +35% . Maris-Tech ( MTEK ) +35% . Lexicon Pharmaceuticals ( LXRX ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Maxim Group LLC, a full-service investment banking, securities and wealth management firm, and M-Vest, a digital community built for issuers, investors, and thought leaders, present the 2024 Healthcare IT Virtual Conference. The conference will take pla...
Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, is providing a crucial update regarding recent decisions that will imp...
Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel gr...